Stuttgart - Delayed Quote EUR

Roche Holding AG (RHO6.SG)

28.05

-1.09

(-3.75%)

As of 3:34 PM GMT+2. Market Open.

Loading Chart for RHO6.SG

9/21 12:03 PM

DELL

Previous Close 29.14
Open 28.79
Bid 27.99 x 878200
Ask 28.59 x 863700
Day's Range 28.05 - 28.79
52 Week Range 27.38 - 37.43
Volume 0
Avg. Volume 72
Market Cap (intraday) --
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) --
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

$Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study$

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

$[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study$

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

Roche Annual General Meeting 2024

Roche Annual General Meeting 2024

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

RHO6.SG

10.81%

MSCI WORLD

5.05%

1-Year Return

RHO6.SG

17.35%

MSCI WORLD

0.00%

3-Year Return

RHO6.SG

10.30%

MSCI WORLD

13.01%

5-Year Return

RHO6.SG

16.36%

MSCI WORLD

53.12%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Roche Holding AG

28.05

-3.75%

Mkt Cap EUR -

Industry Drug Manufacturers—General

96.00

0.00%

Mkt Cap 198.949B

Industry Drug Manufacturers—General

JOHNSON & JOHNSON CDR (CAD HEDG

19.82

-1.29%

Mkt Cap CAD 487.356B

Industry Drug Manufacturers—General

6.43

-0.77%

Mkt Cap 5.518B

Industry Drug Manufacturers—General

89.33

+0.44%

Mkt Cap CHF 182.27B

Industry Drug Manufacturers—General

88.29

-0.63%

Mkt Cap EUR 110.206B

Industry Drug Manufacturers—General

Bayer Aktiengesellschaft

27.06

-1.06%

Mkt Cap EUR 26.579B

Industry Drug Manufacturers—General

40.84

-0.97%

Mkt Cap 83.437B

Industry Drug Manufacturers—General

273.98

+0.16%

Mkt Cap 146.956B

Industry Drug Manufacturers—General

98.07

+0.81%

Mkt Cap 200.565B

Industry Drug Manufacturers—General

Bristol-Myers Squibb Company

48.87

-0.24%

Mkt Cap 99.048B

Industry Drug Manufacturers—General

Valuation Measures

As of 4/23/2024

Market Cap

190.70B
Enterprise Value

211.56B
Trailing P/E

15.83
Forward P/E

12.90
PEG Ratio (5yr expected)

1.54
Price/Sales (ttm)

3.01
Price/Book (mrq)

6.16
Enterprise Value/Revenue

3.50
Enterprise Value/EBITDA

11.41

Financial Highlights

Profitability and Income Statement

Profit Margin

--
Return on Assets (ttm)

--
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

--
Diluted EPS (ttm)

--

Balance Sheet and Cash Flow

Total Cash (mrq)

--
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

--

RHO6.SG does not have Company Insights

NOTA.F Novartis AG

91.40

-0.44%

RHO6.BE Roche Holding AG

28.20

-3.42%

GS71.DE GSK plc

19.14

-0.29%

ZEG.DE AstraZeneca PLC

132.80

+0.95%

RHO6.F Roche Holding AG

28.10

-1.71%

NOTA.DU Novartis AG

90.80

+0.67%

0O59.IL Sanofi

88.28

-0.55%

6MK.DE Merck & Co., Inc.

117.80

-0.84%

NOVNEE.SW Novartis AG

89.60

0.00%